Gastroenteropancreatic Neuroendocrine Tumors Withdrawn Phase 1 / 2 Trials for Lutetium Lu 177 dotatate (DB13985)

Back to Gastroenteropancreatic Neuroendocrine Tumors

Also known as: Gastro-entero-pancreatic Neuroendocrine Tumor / Gastro-entero Pancreatic Neuroendocrine Tumors / Gastro Entero Pancreatic Neuroendocrine Tumors / Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) / Neuroendocrine Gastroenteropancreatic Tumour / Gastro-entero-pancreatic Neuroendocrine Tumors / GEP-NET / Gastro-enteropancreatic Neuroendocrine Tumor / Gastro-Entero-Pancreatic Tumors (GEPs) / Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) / Neuroendocrine Tumors,Gastroenteropancreatic / Gastroenteral-Pancreatic Neuroendocrine Tumors / Gastroenteropancreatic Neuroendocrine Tumours / Gastroenteropancreatic Neuroendocrine Tumor / Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET) / Gastroenteropancreatic Neuroendocrine Tumor Disease / Gep Net / Gastroenteropancreatic neuroendocrine tumour disease

Indication	Status	Phase
DBCOND0063370 (Gastroenteropancreatic Neuroendocrine Tumors)	Withdrawn	1 / 2

clinicaltrials.gov Identifier	Title	Purpose	Drugs
NCT04614766	A Clinical Trial Evaluating the Safety of Combining Lutathera(R) and Azedra(R) to Treat Mid-gut Neuroendocrine Tumors	Treatment	Iobenguane (DB06704) Lutetium Lu 177 dotatate (DB13985)